Physician profile
William Kyle
NPI 1770758351
$2,017.03
in general payments reported to CMS, 2019-2025
26 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $112 · 2021: $143 · 2022: $138 · 2023: $399 · 2024: $535 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,329.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $358.49 | 2019-2025 | |
| Novo Nordisk INC | $305.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $233.86 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Lilly USA, LLC | $182.26 | 2019-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $145.06 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.78 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $97.34 | 2019-2024 | Watchman Flx |
| Exact Sciences Corporation | $75.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $61.38 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $46.82 | 2019-2020 | |
| Abbott Laboratories | $43.36 | 2023-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $39.96 | 2019-2024 | Veozah |
| Actelion Pharmaceuticals US, INC. | $35.08 | 2024 | Opsumit |
| Inspire Medical Systems, INC. | $34.70 | 2025 | Inspire |
| Eisai INC. | $33.35 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $32.68 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $30.57 | 2023-2024 | Arexvy, Shingrix |
| Abbvie INC. | $25.04 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.40 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $20.16 | 2021 | |
| Daiichi Sankyo INC. | $19.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.23 | 2025 | |
| Esperion Therapeutics, INC. | $16.20 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $14.44 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2020 | |
| Shire North American Group INC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.